Dexmedetomidine HCl

DEXMEDETOMIDINE HCL

Manufacturer: Medical Purchasing Solutions, LLC

Score: 145.0

Quick Summary

Dexmedetomidine HCl is a relatively selective alpha 2-adrenergic agonist used for sedation of non-intubated patients prior to and/or during surgical and other procedures. It has a rapid distribution phase and a terminal elimination half-life of approximately 2 hours. The most common adverse reactions include hypotension, bradycardia, and dry mouth. Dosage should be individualized and titrated to desired clinical effect, with a recommended initial dose of 1 mcg/kg over 10 minutes, followed by a maintenance infusion of 0.6 mcg/kg/hour. Special population considerations include use during pregnancy, nursing mothers, pediatric use, and geriatric use.

Key Clinical Findings and Indications

Sedation of non-intubated patients prior to and/or during surgical and other procedures
Relatively selective alpha 2-adrenergic agonist
Rapid distribution phase and terminal elimination half-life of approximately 2 hours

Important Safety Information

Warning

Hypotension, bradycardia, and dry mouth are common adverse reactions

Contraindications

Adverse Reactions

Hypotension
Bradycardia
Dry mouth
Respiratory depression
Hypertension
Tachycardia
Nausea
Hypoxia

Dosing Recommendations

General Guidance

Dosage should be individualized and titrated to desired clinical effect

Procedural sedation

Adult Dose

1 mcg/kg over 10 minutes, followed by a maintenance infusion of 0.6 mcg/kg/hour

Pediatric Dose

Not established

Special Population Considerations

Pregnancy

Category C
No adequate and well-controlled studies in pregnant women
Fetal exposure should be expected

Nursing Mothers

Caution should be exercised when administering to a nursing woman
Radio-labeled dexmedetomidine was excreted in milk in lactating female rats

Pediatric Use

Safety and efficacy have not been established
The use of dexmedetomidine for procedural sedation in pediatric patients has not been evaluated

Geriatric Use

A reduced loading dose of 0.5 mcg/kg given over 10 minutes is recommended
A reduction in the maintenance infusion should be considered for patients greater than 65 years of age